Nanomedicine approaches to improve cancer immunotherapy

Significant advances have been made in the field of cancer immunotherapy by orchestrating the body's immune system to eradicate cancer cells. However, safety and efficacy concerns stemming from the systemic delivery of immunomodulatory compounds limits cancer immunotherapies expansion and application. In this context, nanotechnology presents a number of advantages, such as targeted delivery to immune cells, enhanced clinical outcomes, and reduced adverse events, which may aid in the delivery of cancer vaccines and immunomodulatory agents. With this in mind, a diverse range of nanomaterials with different physicochemical characteristics have been developed to stimulate the immune system and battle cancer. In this review, we will focus on some recent developments and the potential advantages of utilizing nanotechnology within the field of cancer immunotherapy. For further resources related to this article, please visit the WIREs website. Several strategies of nanoimmunotherapy have been developed to kill cancer cells. Nanoparticles(NPs) can delivery adjuvants to induce dendritic cell (DC) maturation, meanwhile NPs can easily co‐deliver tumor antigens and adjuvants to DCs ensuring effective activation and presentation. Additionally, NPs can restore T cell antitumor function by delivering CTLA‐4 or PD‐1/PD‐L1 antibodies that stop anergy.
Source: Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology - Category: Nanotechnology Authors: Tags: Advanced Review Source Type: research